■ Pixium Vision’s remote rehabilitation system for patients enrolled in the PRIMAvera pivotal trial and the French Feasibility Study in atrophic dry age-related macular degeneration (AMD) was granted approval, the company said in a news release. The patient engagement platform, requiring only a Pixium-provided tablet and internet connection, will allow patients to conduct rehabilitation sessions from home. The company noted that it will be adding more features to the platform “to help dry AMD patients live a more independent life.”

The platform allows clinicians to track the progress of patients at any time and adjust the frequency of the remote rehabilitation sessions based on their progress. Remote rehabilitation will make it simpler for patients to comply, given their age and lack of vision, according to the company. A readout of the PRIMAvera study should happen at the end of 2023 and a regulatory submission in Europe in the first half of 2024, according to the company.